Guerbet Group Overview

  • Year Founded
  • 1926

Year Founded

  • Status
  • Public

  • Employees
  • 1,057


  • Stock Symbol
  • GBT

Stock Symbol

  • Investments
  • 7

  • Share Price
  • $41.03
  • (As of Monday Closing)

Guerbet Group General Information


Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic purposes. Its products include medical imaging contrast products for x-ray imaging, magnetic resonance imaging, ultrasound imaging and for nuclear medicine. The company markets its products under the brand names such as Xenetix, Optiray, Oxilan, Telebrix, Lipiodol, Dotarem, Endorem, Artirem, Lumirem, and Lipiodol.

Contact Information

Ownership Status
Publicly Held
Financing Status
Primary Industry
Diagnostic Equipment
Stock Exchange
Corporate Office
  • 15 Rue Des Vanesses
  • Zone Paris Nord II
  • 93420 Villepinte
  • France
+33 01 00 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Guerbet Group Stock Performance

(As of Monday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$41.03 $42.51 $16.21 - $43.88 $517M 12.6M 11.4K $1.89

Guerbet Group Financials Summary

In Thousands,
TTM 31-Dec-2023 FY 2023 31-Dec-2023 FY 2022 31-Dec-2022 FY 2021 31-Dec-2021
EV 562,431 562,431 422,416 766,504
Revenue 860,958 860,958 809,053 870,067
EBITDA 110,874 110,874 38,886 106,643
Net Income 25,825 25,825 (43,229) 38,587
Total Assets 1,133,302 1,133,302 1,007,671 1,133,164
Total Debt 424,009 424,009 333,827 376,511
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Guerbet Group Valuation & Funding

Deal Type Date Amount Valuation/
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Guerbet Group‘s full profile, request access.

Request a free trial

Guerbet Group Comparisons

HQ Location
Total Raised
Post Valuation
Guerbet SA is a healthcare company that manufactures and markets medical imaging contrast agents destined for diagnostic
Diagnostic Equipment
Villepinte, France
1,057 As of 2023

00 000

unt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exer
0000000000 000000000
Chicago, IL
00000 As of 0000
0000 0000.


inim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea com
0000000000 000000000
Montclair, NJ
0 As of 0000
000000000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Guerbet Group Competitors (5)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
GE Healthcare Corporation Chicago, IL 00000 0000 0000.
FluoroPharma Formerly VC-backed Montclair, NJ 0 0000 000000000 0000
Lantheus Medical Imaging Formerly PE-Backed North Billerica, MA 000 00.000 000000000 00 00.000
Infraredx Formerly VC-backed Bedford, MA 000 00000 000000&0 00000
Analogic Private Equity-Backed Peabody, MA 000 000.00 000000000 000.00
You’re viewing 5 of 5 competitors. Get the full list »

Guerbet Group Patents

Guerbet Group Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4336442-A1 Method for characterizing an organ of a patient in a medical image Pending 09-Sep-2022 0000000000 0
EP-4311512-A1 Computer-implemented method of liver resection planning Pending 29-Jul-2022 000000000
EP-4307218-A1 Method for classifying a medical image of an organ of a patient Pending 12-Jul-2022 000000000
EP-4299080-A1 Radio-opaque monomer and embolisation microspheres comprising same Pending 28-Jun-2022 00000000000 0
FR-3134316-A1 Medical faucet Active 11-Apr-2022 A61M39/223 0
To view Guerbet Group’s complete patent history, request access »

Guerbet Group Executive Team (11)

Name Title Board Seat
David Hale Chief Executive Officer
Jérôme Estampes Group Chief Financial Officer & Senior Vice President, Business Development & Licensing
Marcello Bellato Chief Information Officer
François Nicolas Ph.D Chief Digital Officer, R&I & Senior Vice President, Research & Development
Valérie Brissart Senior Vice President Marketing - Diagnostic Imaging
You’re viewing 5 of 11 executive team members. Get the full list »

Guerbet Group Board Members (5)

Name Representing Role Since
000000 00000000 Guerbet Group Board Member 000 0000
000000 000000 Self Board Member 000 0000
000000 0000000-000 Guerbet Group Board Member 000 0000
00000000 000000 Guerbet Group Board Member 000 0000
You’re viewing 4 of 5 board members. Get the full list »

Guerbet Group Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Guerbet Group Investments & Acquisitions (7)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Intrasense 05-Jun-2023 0000000000 Other Healthcare Technology Systems 00000 000
Intrasense 11-Jan-2023 0000 00.00 Other Healthcare Technology Systems
Accurate Medical Therapeutics 02-Aug-2018 0000000000 000.00 Surgical Devices 0000 0'00
Occlugel (laboratory-stage technology) 26-Apr-2018 000000000 00.000 Buildings and Property
Mallinckrodt (CMDS Business) 27-Nov-2015 Merger/Acquisition 00000 Diagnostic Equipment 0000 0'00
You’re viewing 5 of 7 investments and acquisitions. Get the full list »

Guerbet Group Subsidiaries (5)

Company Name Industry Location Founded
Guerbet France Distributors/Wholesale Villepinte, France 2012
Intrasense Other Healthcare Technology Systems Montpellier, France 0000
Guerbet Laboratories Distributors/Wholesale Solihull, United Kingdom 0000
Medex Biomedical Drug Delivery Saint Priest, France 0000
Simafex Other Chemicals and Gases Marans, France 0000
To view Guerbet Group’s complete subsidiaries history, request access »

Guerbet Group ESG

Risk Overview

Risk Rating

Updated February, 08, 2024

17.54 | Low Risk

Risk Scale

A lower score indicates better sustainability












Exposure refers to the extent to which a company is exposed to different material ESG issues



Management is related to actions taken to manage ESG issues


Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.


Covered Companies

00 of 16,216






00 of 643




Medical Supplies


00 of 58




To view Guerbet Group’s complete esg history, request access »

Guerbet Group FAQs

  • When was Guerbet Group founded?

    Guerbet Group was founded in 1926.

  • Who is the CEO of Guerbet Group?

    David Hale is the CEO of Guerbet Group.

  • Where is Guerbet Group headquartered?

    Guerbet Group is headquartered in Villepinte, France.

  • What is the size of Guerbet Group?

    Guerbet Group has 1,057 total employees.

  • What industry is Guerbet Group in?

    Guerbet Group’s primary industry is Diagnostic Equipment.

  • Is Guerbet Group a private or public company?

    Guerbet Group is a Public company.

  • What is Guerbet Group’s stock symbol?

    The ticker symbol for Guerbet Group is GBT.

  • What is the current stock price of Guerbet Group?

    As of 22-Jul-2024 the stock price of Guerbet Group is $41.03.

  • What is the current market cap of Guerbet Group?

    The current market capitalization of Guerbet Group is $517M.

  • What is Guerbet Group’s current revenue?

    The trailing twelve month revenue for Guerbet Group is $861M.

  • Who are Guerbet Group’s competitors?

    GE Healthcare, FluoroPharma, Lantheus Medical Imaging, Infraredx, and Analogic are competitors of Guerbet Group.

  • What is Guerbet Group’s annual earnings per share (EPS)?

    Guerbet Group’s EPS for 12 months was $1.89.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »